Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.
Quethera will present pre-clinical efficacy data at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Baltimore, MD (7th-10 May 2017).
ARVO is the biggest eye research meeting in the world and the team will present evidence that the Quethera glaucoma gene therapy construct significantly enhances retinal ganglion cell survival after optic nerve injury. Two poster presentations from the Quethera team will outline the work which led to the design of the novel gene therapy construct and Prof. Keith Martin will deliver an oral presentation in the plenery Neuroprotection session showing the safety and efficacy of the Quethera construct in glaucoma animal models.
Best glaucoma poster award to Quethera and Cambridge University at the European Association for Vision and Eye Research (EVER) 2016-10-06
Quethera and the Cambridge University Department of Clinical Neurosciences awarded the prize for the best poster in the glaucoma section at the European Association for Vision and Eye Research (EVER) on 5th October 2016 in Nice, France. The poster entitled “Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus” was presented by Dr. Tasneem Khatib.
Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in Cambridge, has obtained a grant from the Wellcome Trust Pathfinder Award Scheme. Quethera was founded in 2013 to treat glaucoma using gene therapy. It received seed funding last year from the Rainbow Seed Fund and Cambridge Enterprise, the commercialisation arm of the University of Cambridge.
Dr Peter S. Widdowson, CEO and co-Founder of Quethera said “we are absolutely delighted to receive this award which will further assist in the optimisation and design of our novel gene construct aimed at preventing further sight loss in patients with glaucoma.”
Keith Martin, Professor of Ophthalmology at the University of Cambridge and co-Founder of Quethera said “we are very pleased that the Wellcome Trust has recognised the value of our work and we appreciate this support as we continue to develop new therapies that will make a real difference to the lives of people losing vision due to glaucoma.”
The Wellcome Trust is a global charitable foundation dedicated to improving health, supporting bright minds in science, the humanities and the social sciences, as well as education, public engagement and the application of research to medicine. Its investment portfolio gives it the independence to support such transformative work as the sequencing and understanding of the human genome, research that established front-line drugs for malaria, and Wellcome Collection, a free venue for the incurably curious that explores medicine, life and art.